[Results obtained from gestagen treatment of patients for endometrial carcinoma, with particular reference to results obtained from in vitro tests before treatment (author's transl)].
Reported in this paper is a retrospective review of two-year survival of 280 patients with endometrial carcinoma, with 22 per cent of them having received additional progestagen therapy. Survival rates were more favourable in response to progestagen therapy, particularly in the context of advanced stages. The best results were achieved by individual progestagen therapy preceded by pretherapeutic sensitivity testing.
D000077713:17 alpha-Hydroxyprogesterone Caproate; D004351:Drug Resistance; D005260:Female; D006801:Humans; D006908:Hydroxyprogesterones / Q000627:therapeutic use*; D009367:Neoplasm Staging; D009640:Norethindrone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077563:Norethindrone Acetate; D009644:Norgestrel / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
D006908:Hydroxyprogesterones; D000077713:17 alpha-Hydroxyprogesterone Caproate; D009644:Norgestrel; D000077563:Norethindrone Acetate; D009640:Norethindrone
Ergebnisse der Gestagentherapie von Endometriumkarzinomen unter besonderer Berücksichtigung prätherapeutischer In-vitro-Testergebnisse.